drugset / Trial / NCT00385398
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
Phase 2
Withdrawn
University of Medicine and Dentistry of New Jersey
Genentech, Inc. · collabNational Cancer Institute (NCI) · collabSchering-Plough · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Treatment with radiosurgery, temozolomide, and erlotinib may affect brain function (the ability to think, learn, remember, and judge) in patients with non-small cell lung cancer and brain metastases. A study that evaluates brain function may help doctors plan the best treatment. PURPOSE: This phase II trial is studying the effect of radiosurgery, temozolomide, and erlotinib on brain function in patients with non-small cell lung cancer and brain metastases.
Timeline
- Start
- 2008-07
- Primary completion
- 2008-12
- Completion
- 2008-12
Outcome
Outcome not reported
Stopped (Business): “lack of funding and drug supply”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 200 mg | Oral |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |